Logistics Articles

51. Cancer Care's Evolving Recovery And Remission Phase Demands Evolved Medical Devices 6/6/2016

    Cancer research receives a huge share of global R&D spending, driving lots of innovation in therapies and changing the landscape of the remission and recovery phases, in particular. However, the availability of drugs on self-administration device platforms is one element of cancer care that is not aligned with a non-clinical, long-term care model. Herein lies a great opportunity for medical device manufacturers. 

52. Understanding (And Securing) Medicare Coverage During Med Device Clinical Trials 6/3/2016

    Obtaining coverage during clinical trials should be considered as part of a comprehensive reimbursement plan, coordinated with the clinical studies and regulatory plans, all of which are necessary parts of a complete business plan.

53. Outsourcing Insights For Drug Delivery Devices 6/1/2016

    Windgap Medical's wet/dry epinephrine delivery device is in its third generation of prototype development, and the company has fought through the gauntlet of outsourcing decisions. Here, CEO Chris Stepanian discusses outsourcing methodology, including which functions to outsource, vetting of potential partners, and more. 

54. Innovative vs. Intuitive: 5 Ways To Ensure Novelty Doesn't Compromise Usability 5/16/2016

    Innovation can often upset the apple cart, especially in cases where new and unfamiliar technologies are utilized to enable new functionality. This less-than-optimal user experience can hurt the product’s adoption and lead to high rates of abandonment. Here are five suggestions to ensure that new designs lead to safe, effective, and desirable outcomes.

55. China's Diagnostic Imaging System Market: Foreign Vendor Opportunities & Challenges 5/12/2016

    The first part of this article examined how China’s healthcare reform, within the context of the 13th Five-Year Plan, affected Chinese diagnostic imaging vendors. Here, we examine the role of foreign manufacturers, as well as the challenges and opportunities they face. 

56. China's Diagnostic Imaging System Market: Healthcare Reform & Domestic Companies' Advantage 5/9/2016

    China's course toward national development has placed healthcare reform front and center. An expanding middle class — with expanding global connectivity — is increasingly demanding congruency with Western healthcare standards. This two-part article outlines key challenges and opportunities resultant of China’s 13th Five-Year Plan and healthcare reform, starting with a look at domestic systems' place in the imaging market.

57. 3 Vital Considerations For Medtechs Mulling A Hospital Partnership 5/5/2016

    Each medtech company must consider carefully how its products and services fit its customers’ needs. Some may pursue (or continue) a category-killer approach, and dominate a narrow channel. Others may choose to be market disrupters and produce game-changing technologies. Most of today’s medtech companies have taken a blended approach, but the opportunities to partner with providers in the new outcomes-based healthcare paradigm are enticing.

58. The Medical Science Liaison Officer: A Smart Addition To The Medtech Team 5/3/2016

    A medical science liaison officer (MSLO) has long been a common, highly valued position in pharmaceutical companies, healthcare systems, and clinical research organizations. This role is designed to bridge the gap between the company’s perspective, medical science, healthcare professionals, patients, and payers. As non-medical people have less access to health plan medical policy people, the MSLO role has expanded to the medtech and biotech industries.

59. 3 Strategies For Expanding Global Access To Your Medical Device: A Radiotherapy Case Study 4/22/2016

    Fourteen million people worldwide were diagnosed with cancer in 2012, and experts predict 22 million people will receive a cancer diagnosis in 2030. Here, we examine how the processes used to broaden access to radiotherapy can readily be adapted by other members of the medical device community to improve the treatment of cancer patients and to create additional market value.

60. A Comprehensive Guide To The U.S. TAVR Market: Looking Ahead 4/18/2016

    The second article in a two-part series examining the past, present, and future of the U.S. transcatheter aortic valve replacement (TAVR) market, this installment examines what it will take for TAVRs to become the standard of care for low-, intermediate-, and high-risk patients with severe symptomatic aortic stenosis. It also looks at major competitors in the space and emerging opportunities.